Quickstart Highlights
PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
- Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
- Typical daily range: 100–500 mcg once daily (gradual titration).
- Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = 10 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 unit (0.01 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established[3]. Any dosing above a few hundred micrograms per day is purely speculative[4].
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (PNC-27, 30 mg each):
- 8 weeks ≈ 1 vial (~15–20 mg total used)
- 12 weeks ≈ 1 vial (~25 mg total used)
- 16 weeks ≈ 2 vials (~35–40 mg total used)
- Insulin Syringes (U‑100 or 30/50‑unit for precision):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
![Peptide Vial](http://www.dosagepeptide.com/wp-content/uploads/2025/12/Generic-Vial-scaled.png" alt="PNC-27 (30 mg Vial)" /></div>)
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
- Start: 100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
- Target: 300–500 mcg daily by Weeks 5–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality[5].
- Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Regulatory Warning: PNC-27 has no FDA approval and no established human safety data[3]. This information is strictly educational.
How This Works
PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.
Lifestyle Factors
General supportive strategies (not specific to PNC-27).
- Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
- Prioritize adequate sleep and stress management for immune and recovery support.
- Consult qualified healthcare professionals before any experimental peptide use.
Potential Benefits & Side Effects
Observations from preclinical literature only—no human data available.
- Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells[2][6].
- Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7].
- No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3].
- Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.
Injection Technique
Recommended Source
We recommend Prime Lab Peptides for high‑purity PNC-27 (30 mg).
Why Prime Lab Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is for educational purposes only and is not medical advice. PNC-27 is an unapproved experimental compound with no established human safety or efficacy data[3].
References
-
Journal of Biomedical Science (2017)
— Review of therapeutic peptides; PNC-27 mechanism and cancer cell selectivity -
Cancer Chemotherapy and Pharmacology (2010)
— PNC-27 induces tumor cell membrane lysis; preclinical mechanism study -
FDA Drug Safety Communication (2015)
— Warning: PNC-27 is unapproved; safety not established -
International Journal of Cancer (2006)
— PNC-28 (related peptide) blocks pancreatic cancer growth in vivo; mouse model study -
Peptide Sciences
— Peptide storage guidelines: lyophilized and reconstituted stability -
BMC Cancer (2008)
— PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption -
PubMed (2012)
— PNC-27 peptide induces necrosis via direct membrane lysis mechanism -
CDC
— Vaccine administration: subcutaneous route (angle/site guidance) -
National Hemophilia Foundation (2021)
— Subcutaneous injection guidelines: needle length, angle, site preparation -
NCBI Bookshelf
— Best practices for injection (asepsis, preparation, and administration) -
Subcutaneous Drug Injection Review (PMC)
— Pharmacologic considerations of the subcutaneous route